AstraZeneca 2Q Revenues: $6.5 billion (+4%) 2Q Earnings: $796 million (+9%) YTD Revenues: $12.9 billion (+2%) YTD Earnings: $1.3 billion (-4%) Comments: Diabetes sales were up 128% following the integration of BMS assets and strong U.S. Farxiga launch. Brilinta sales were up 84% in the quarter to $117 million. Crestor sales were down 2% (CER) to $1.5 million. Symbicort sales were $928 million, up 9% (CER). Nexium sales were down 4% (CER) to $971 million. U.S. revenues were up 8%. Declining ...